A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Lubiprostone for the Treatment of Opioid-Induced Bowel Dysfunction in Patients With Chronic, Non-Cancer Pain

被引：0
|
作者：
Cryer, Byron L.
Katz, Seymour
Vallejo, Ricardo
Scott, Charles B.
Joswick, Taryn R.
Dolecek, Gayle
Ueno, Ryuji
机构：
来源：
GASTROENTEROLOGY | 2010年 / 138卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
906
引用
收藏
页码：S129 / S129
页数：1
相关论文
共 50 条
  • [1] Lubiprostone Significantly Improves Treatment Response in Non-Methadone Opioid-Induced Bowel Dysfunction Patients with Chronic, Non-Cancer Pain: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial
    Jamal, M. Mazen
    Mareya, Shadreck M.
    Woldegeorgis, Fasil
    Joswick, Taryn R.
    Joswick, Ryuji Ueno
    GASTROENTEROLOGY, 2012, 142 (05) : S144 - S145
  • [2] Lubiprostone Is Well Tolerated in Chronic Non-Cancer Pain Patients With Opioid-Induced Constipation in Three Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials
    Lichtlen, Peter
    Joswick, Taryn
    Woldegeorgis, Fasil
    Ueno, Ryuji
    GASTROENTEROLOGY, 2013, 144 (05) : S916 - S916
  • [3] Time to Onset of Lubiprostone Treatment Effect in Chronic Non-Cancer Pain Patients With Opioid-Induced Constipation: Data From Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials
    Joswick, Taryn
    Mareya, Shadreck M.
    Lichtlen, Peter
    Woldegeorgis, Fasil
    Ueno, Ryuji
    GASTROENTEROLOGY, 2013, 144 (05) : S540 - S540
  • [4] A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Chronic Non-Cancer Pain
    Webster, Lynn Roy
    Yamada, Tadaaki
    Ferreira, Juan Camilo Arjona
    Davidson, Jennifer
    GASTROENTEROLOGY, 2015, 148 (04) : S1194 - S1194
  • [5] A Randomized, Placebo-Controlled Trial of Lubiprostone for Opioid-Induced Constipation in Chronic Noncancer Pain
    Jamal, M. Mazen
    Adams, Atoya B.
    Jansen, Jan-Peter
    Webster, Lynn R.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 (05): : 725 - 732
  • [6] A phase 2a, randomized, double-blind, placebo-controlled, single ascending-dose study to evaluate the safety and efficacy of naldemedine in patients with chronic non-cancer pain and opioid-induced bowel dysfunction
    Webster, L.
    Nagata, T.
    Yamada, T.
    Ferreira, J. Arjona
    JOURNAL OF PAIN, 2016, 17 (04): : S94 - S94
  • [7] Naldemedine for Opioid-Induced Constipation in Patients With Cancer: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial
    Hamano, Jun
    Higashibata, Takahiro
    Kessoku, Takaomi
    Kajiura, Shinya
    Hirakawa, Mami
    Oyamada, Shunsuke
    Ariyoshi, Keisuke
    Yamada, Takeshi
    Yamamoto, Yoshiyuki
    Takashima, Yasuyuki
    Doki, Kosuke
    Homma, Masato
    Mathis, Bryan J.
    Jono, Tsumugi
    Ogata, Tomoki
    Tanaka, Kosuke
    Kasai, Yuki
    Iwaki, Michihiro
    Fuyuki, Akiko
    Nakajima, Atsushi
    Hayashi, Ryuji
    Ando, Takayuki
    Izawa, Naoki
    Kobayashi, Yuko
    Horie, Yoshiki
    Morita, Tatsuya
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (35)
  • [8] Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer
    Katakami, Nobuyuki
    Oda, Koji
    Tauchi, Katsunori
    Nakata, Ken
    Shinozaki, Katsunori
    Yokota, Takaaki
    Suzuki, Yura
    Narabayashi, Masaru
    Boku, Narikazu
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (17) : 1921 - +
  • [9] A phase II randomized, double-blind, placebo-controlled study to evaluate naldemedine for the treatment of opioid-induced constipation (OIC) in patients with cancer pain
    Boku, Narikazu
    Katakami, Nobuyuki
    Fujita, Shiro
    Oda, Koji
    Tauchi, Katsunori
    Nakata, Ken
    Shinozaki, Katsunori
    Okuno, Motoyasu
    Kawai, Yasukazu
    Kikukawa, Hiroaki
    Suzuki, Ryujiro
    Nakazawa, Hideo
    Kojima, Hiroshi
    Mizutani, Mitsuhiro
    Hara, Toru
    Yokota, Takaaki
    Suzuki, Yura
    Narabayashi, Masaru
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Long-Term Safety and Efficacy of Lubiprostone in Opioid-Induced Bowel Dysfunction in Patients with Chronic, Non-Cancer Pain: Results of a Phase 3, Open-Label Clinical Trial
    Spierings, Egilius
    Joswick, Taryn
    Lindner, Elizabeth
    Woldegeorgis, Fasil
    Ueno, Ryuji
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S138 - S139
12345